

<b>Statement of Deficiencies</b>	<b>(X1) Provider/Supplier/CLIA Identification Number</b>  23D2149322	<b>(X3) Date Survey Completed</b>  05/29/2019
<b>Name of Provider or Supplier</b>  Pioneer Central Medical Laboratory Llc	<b>Street Address, City, State</b>  15230 Levan Road Level B, Livonia, MI	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

<b>(X4) ID Prefix Tag</b>	<b>Summary Statement of Deficiencies</b>
<b>D5309</b>	<p>TEST REQUEST CFR(s): 493.1241(e)</p> <p>If the laboratory transcribes or enters test requisition or authorization information into a record system or a laboratory information system, the laboratory must ensure the information is transcribed or entered accurately.</p> <p>This STANDARD is not met as evidenced by:                      . Based on record review and interview with the laboratory director, the laboratory failed to enter test requisitions accurately for five (#1 - #5) of five patients reviewed. Findings include: 1. Record review of patients (#1-#5) test requisitions and final reports from December 2018 to May 2019 revealed the following discrepancies: Patient #1 a. The test requisition revealed a "Confirmation Panel" was ordered. b. The "Confirmation Panel" signed by the ordering physician on 12/28/18 included the following tests that were not on the final report: Pentazocine, Nalbuphine, Propoxyphene, Normeperidine, Butorphanol, Flunitrazepam. Flurozepam, LSD, Bath Salts, Methylone, and Fluoxetine. c. The final report included the following tests not indicated in the "Confirmation Panel": Gabapentin and Pregabalin. Patient #2 a. The test requisition revealed "Confirmation Panel" was ordered. b. The "Confirmation Panel" signed by the ordering physician on 02/05/19 included the following tests that were not on the final report: Pentazocine, Nalbuphine, Propoxyphene, Normeperidine, Butorphanol, Flunitrazepam. Flurozepam, LSD, Bath Salts, Methylone, and Fluoxetine. c. The final report included the following tests not indicated in the "Confirmation Panel": Gabapentin and Pregabalin. Patient #3 a. The test requisition revealed "Confirmation Panel" was ordered. b. The "Confirmation Panel" signed by the ordering physician on 03/19/19 included the following tests that were not on the final report: Pentazocine, Nalbuphine, Propoxyphene, Normeperidine, Butorphanol, Flunitrazepam. Flurozepam, LSD, Bath Salts, Methylone, and Fluoxetine. c. The final report included the following tests not indicated in the "Confirmation Panel": Zaleplon, Gabapentin, and Pregabalin Patient #4 a. The test requisition revealed</p>

"Confirmation Panel" was ordered. b. The "Confirmation Panel" signed by the ordering physician on 04/05/19 included the following tests that were not on the final report: Pentazocine, Nalbuphine, Propoxyphene, Normeperidine, Butorphanol, Flunitrazepam. Flurozepam, LSD, Bath Salts, Methylone, and Fluoxetine. c. The final report included the following tests not indicated in the "Confirmation Panel": Zaleplon, Gabapentin, and Pregabalin. Patient #5 a. The test requisition revealed "Confirmation Panel" was ordered. b. The "Confirmation Panel" signed by the ordering physician on 05/08/19 included the following tests that were not on the final report: Pentazocine, Nalbuphine, Propoxyphene, Normeperidine, Butorphanol, Flunitrazepam. Flurozepam, LSD, Bath Salts, Methylone, and Fluoxetine. c. The final report included the following tests not indicated in the "Confirmation Panel": Zaleplon, Gabapentin, and Pregabalin 2. During the interview on May 29, 2019 at approximately 1:00 PM, the laboratory director acknowledged there were discrepancies between the test requisitions and test reports.